Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

2 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

30-day readmission predicts mortality in hospitalized CDI patients with cirrhosis

01 Sep 2019

A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.

A total of 12,274 out of 366,283 (3.4 percent) patients hospitalized with CDI had cirrhosis. Of these, 7,741 (63.1 percent) were decompensated. Among CDI patients, those with vs without cirrhosis had higher 30-day readmission rates (33 percent vs 24 percent), index admission mortality (5 percent vs 2.5 percent) and calendar-year mortality (9 percent vs 4 percent).

The most common reasons for readmission were recurrent CDI (46 percent) and cirrhosis-related complications (34.6 percent). Patients with decompensated cirrhosis had a greater risk of readmission within 30 days than those with compensated cirrhosis (odds ratio [OR], 1.19, 95 percent CI, 1.03–1.36).

In multivariable analyses, index colectomy (OR, 6.50, 1.61–26.24) and decompensation (OR, 3.61, 2.49–5.23) predicted index admission mortality among patients with cirrhosis. Thirty-day readmission (OR, 3.71, 2.95–4.67) and decompensated cirrhosis (OR, 1.49, 1.17–1.89) were also independent predictors of calendar-year mortality.

“Reducing [recurrent] CDI-related readmissions may potentially improve these outcomes,” the investigators said.

This study used the Nationwide Readmission Database (2011–2014) to identify hospitalized patients with CDI and differentiate them according to the presence of cirrhosis. Baseline characteristics, surgical rates and outcomes were obtained. The primary outcomes were readmission and mortality rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

2 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.